Etanercept for the Treatment of Human Immunodeficiency Virus-Associated Psoriatic Arthritis, Mayo Clinic Proceedings, vol.75, issue.10 ,
DOI : 10.4065/75.10.1093
Yang A Femoral head avascular necrosis: MR imaging with clinical-pathologic andradionnclide correlation ,
Prevalence and characteristics of rheumatic manifestations in patients infectedwith human immunodeficiency virus undergoing antiretroviral therapy 1 Rheumatol, p.2492, 1997. ,
Septic bursitis in human immunodeficiency virus infection, pp.1374-1380, 1989. ,
Anticardiolipin antibodies associated with RTLV-III infection ,
DOI : 10.1111/j.1365-2141.1988.tb06208.x
Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy, AIDS, vol.15, issue.6, pp.703-712, 2001. ,
DOI : 10.1097/00002030-200104130-00005
Increasing morbidity from myocardial infarction during HIV protease inhibitortreatment? AIDS, pp.1796-1803, 1999. ,
Therapeutic interventions in primary HIV infection, J Acquir Immune Defie Syndr Hum Retrovirol, vol.10, pp.69-76, 1995. ,
Moutsopoulos HM Prevalence of Sjogren's-like syndrome in a cohort of HIV-l-positive patients:descriptive pathology and immunopathology ,
Drug-Induced Lipid Changes, Drug Safety, vol.353, issue.6, pp.443-56, 2001. ,
DOI : 10.2165/00002018-200124060-00003
Cahill PT Segmental patterns of avascular necrosis of the femoral heads: early detectionwith MR imaging Radiology, pp.717-737, 1987. ,
Psoriatic arthritis and human immunodeficiency virus infection in Zambia ,
New concepts in the immunopathogenesis of human immunodeficiency virusinfection ,
Osteonecrosis and human immunodeficiency virus infection ,
et al Dyslipidemia and hyperbaric osteonecrosis in the rat Rev Rhum Mal Osteoartic, pp.8-9615, 1982. ,
MR findings of necrotie lesions and the extra-Iesional area of osteonecrosis of the femoral head Skeletal Radiol2000 Mar, pp.133-174 ,
Risk of developing AIDS after primary acute HIV-1 infection ,
Diagnostic criteria for non-traumatic osteonecrosis of the femoral head ,
Coronary artery disease occurring with protease inhibitor therapy, International Journal of STD & AIDS, vol.9, issue.11 ,
DOI : 10.1258/0956462981921251
14%, respectively, and increase in SQV Cmax by +21%, but 18 APV&SQV decrease of SQV AUC by 19% and Cmin by 48%, 1998. ,
levels 3-fold or higher. Consider dosage of NFV 750 mg + SQV-S 800 mg 3x1d, or NFV 1250 mg + SQV-S 1200 mg 2x1d (under study) (6 th CROI, 1999. ,
Compared with IDV alone, 400 mg of both drugs 2x1d leads to same IDV peak and higher trough levels and acts as true dual-PI combo. No reports of nephrolithiasis in this combination. IDV/RTV 23 IDV&RTV 800/100 mg or 800/200 mg 2x1d augments IDV to higher peak and trough levels without antiviral activity of RTV. No significant food effect on IDV absorption with either dose combination, 1999. ,
APV+NFV results in decrease in APV Cmax by -14%, but increase in AUC by +46% and Cmin by +235%. 26 &EFV No significant effect on NFV levels. The addition of EFV 600 mg qd resulted in same APV Cmax and AUC and mild reduction of Cmin by -14%, 2000. ,
increases IOV lever by 51%; IOV does not affect NFV level. NFV 1250 mg with IOV 1200 mg 2x/d with a low-fat snack on empty stomach shows good drug levels and c1inical efficacy, 1999. ,
450-750 mg + LPV/RTV 2x1d leads to significant decrease of APV Cmin by 220-420% and trend to lower LPV 29 APV Cmin, compared with APV + RTV 100 mg or LPV/RTV alone (historical controls) Additional RTV 100 mg 2xld did not compensate for this interaction, 2001. ,
no change in No change in EFV, 38% J. in rifabutin AUC, consider Î EFV No known interaction rifampin. Unclear significance, no dose change recommended, Iimited data. Q) rifabutin to 450-600 mg 1xld or 600 mg 3x1wk ,
293% Î in rifabutin AUC. J.rifabutin to 150 mg qod if 80% J. in sav AUC and Cmax. dosed with RTV alone ,
Online version, 2001. ,